A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
42actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-10 | actual | When the study began enrolling |
| Primary completion | 2025-09-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-11 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: BMS-986278
- Drug: Placebo
- Drug: Moxifloxacin
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with non-serious Adverse Events (AEs)
measured Until 28 days post last treatment dose
Number of participants with Serious AEs (SAEs)
measured Until 28 days post last treatment dose
Number of participants with AEs leading to study intervention discontinuation
measured Until 28 days post last treatment dose
Number of participants with vital sign abnormalities
measured Up to Day 18
Number of participants with clinical laboratory assessment abnormalities
measured Up to Day 18
Number of participants with 12-lead electrocardiogram (ECG) abnormalities
measured Up to Day 18
Number of participants with physical examination abnormalities
measured Up to Day 18
Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)
measured Up to Day 13 of Period 4 (Each period is 17 days)
Placebo-corrected change from baseline QTcF (ΔΔQTcF)
measured Up to Day 13 of Period 4 (Each period is 17 days)
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed